Publications

Latest publications (18 months)

1           Maharaj AD, Lubel J, Lam E, Clark PJ, Duncan O, George J, et al. Monitoring quality of care in hepatocellular carcinoma: A modified Delphi consensus. Hepatology Communications. 2022.

2.         Lubel JS, Strasser SI, Thompson AJ, Cowie BC, MacLachlan J, Allard NL, et al. Australian consensus recommendations for the management of hepatitis B. The Medical journal of Australia. 2022;216(9):478-86.

3.         Braude M, Roberts S, Majeed A, Lubel J, Prompen J, Dev A, et al. Liver stiffness (Fibroscan(R)) is a predictor of all-cause mortality in people with non-alcoholic fatty liver disease. Liver Int. 2022.

4.         Hall SA, Burns GS, Mooney BJ, Millen R, Morris R, Vogrin S, et al. Hepatitis B Virus Flares following Nucleot(s)ide Analogue Cessation Are Associated with Activation of TLR Signalling Pathways. J Infect Dis. 2022.

5.         Tan N, Ngu N, Worland T, Lee T, Abrahams T, Pandya K, et al. Epidemiology and outcomes of primary sclerosing cholangitis: an Australian multicentre retrospective cohort study. Hepatol Int. 2022.

6.         Hall SAL, Burns GS, Anagnostou D, Vogrin S, Sundararajan V, Ratnam D, et al. Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels. Alimentary pharmacology & therapeutics. 2022.

7.         Méndez-Sánchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, et al. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022;7(5):388-90.

8.         Lubel JS, Strasser SI, Thompson AJ, Cowie BC, MacLachlan J, Allard NL, et al. Australian consensus recommendations for the management of hepatitis B. The Medical journal of Australia. 2022.

9.         Kemp W, Clayton-Chubb D, Majeed A, Glenister KM, Magliano DJ, Lubel J, et al. Impact of renaming NAFLD to MAFLD in an Australian regional cohort: Results from a prospective population-based study. Journal of gastroenterology and hepatology. 2022;37(2):395-403.

10.       Mishra G, Dev A, Paul E, Kemp W, Majeed A, Lubel J, et al. Prognostic factors associated with survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolisation: an Australian multicenter cohort study. Hepatoma Research. 2021;7:56.

11.       Pham AD, Vaz K, Ardalan ZS, Sinclair M, Apostolov R, Gardner S, et al. Clinical outcomes of patients with two small hepatocellular carcinomas. World J Hepatol. 2021;13(10):1439-49.

12.       Lubel JS, Roberts SK, Strasser SI, Shackel N. Australian recommendations for the management of hepatocellular carcinoma (Letter of Reply). The Medical journal of Australia. 2021.

13.       Braude MR, Con D, Lubel J, Bidwai A, Nguyen HT, Sharmamiglani S, et al. Liver disease prevalence and severity in people with serious mental illness: a cross-sectional analysis using non-invasive diagnostic tools. Hepatol Int. 2021.

14.       Roberts SK, Majeed A, Glenister K, Magliano D, Lubel JS, Bourke L, et al. Prevalence of non-alcoholic fatty liver disease in regional Victoria: a prospective population-based study. The Medical journal of Australia. 2021.

15.       Lubel JS, Roberts SK, Strasser SI, Thompson AJ, Philip J, Goodwin M, et al. Australian recommendations for the management of hepatocellular carcinoma: a consensus statement. The Medical journal of Australia. 2021;214(10):475-83.

16.       Lubel JS, Roberts SK, Howell J, Ward J, Shackel NA. Current issues in the prevalence, diagnosis and management of hepatocellular carcinoma in Australia. Internal medicine journal. 2021;51(2):181-8.

17.       Con D, Clayton-Chubb D, Lubel J, Sawhney R, Bloom S. Dynamics of liver stiffness in chronic hepatitis B patients with concurrent metabolic-associated fatty liver disease. Journal of hepatology. 2021.

18.       Prentice RE, Tjandra D, Garg M, Lubel JS, Fourlanos S, Johnson D, et al. Letter: ACE2, IBD and COVID-19-why IBD patients may be at reduced risk of COVID-19. Alimentary pharmacology & therapeutics. 2020;52(8):1422-3.

19.       Howell J, Anderson D, Bloom S, Lubel J, Kemp W, Williams J, et al. Validation of the TREAT-B score for hepatitis B treatment eligibility in a large Asian cohort: TREAT-B improves with age. Journal of hepatology. 2020.

20.       Hirsch RD, Mills C, Sawhney R, Sood S, Bird V, Mishra G, et al. SIRT Compared with DEB-TACE for Hepatocellular Carcinoma: a Real-world Study (the SITAR Study). J Gastrointest Cancer. 2021;52(3):907-14.

Prior publications  (2020 and before)

1.    Hanrahan TP, Lubel JS, Garg M. Letter to the Editor: Lessons from COVID-19, ACE2 and intestinal inflammation - could a virus trigger chronic intestinal inflammation? Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2020.
2.    Rodrigues BT, Mei S, Fox A, Lubel JS, Nicoll AJ. A systematic review on the complications and management of hepatic adenomas: a call for a new approach. Eur J Gastroenterol Hepatol. 2020.
3.    Mishra G, Dev A, Paul E, Cheung W, Koukounaras J, Jhamb A, et al. Prognostic role of alpha-fetoprotein in patients with hepatocellular carcinoma treated with repeat transarterial chemoembolisation. BMC Cancer. 2020;20(1):483.
4.    Lubel J, Garg M. Renin-Angiotensin-Aldosterone System Inhibitors in Covid-19. N Engl J Med. 2020;382.
5.    Garg M, Royce SG, Lubel JS. Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2 - exploring RAS inhibitors. Alimentary pharmacology & therapeutics. 2020.
6.    Garg M, Christensen B, Lubel JS. Letter: Gastrointestinal ACE2, COVID-19 and IBD - opportunity in the face of tragedy? Gastroenterology. 2020.
7.    Tan NP, Majeed A, Roberts SK, Gow PJ, Hey P, Mah X, et al. Survival of patients with ruptured and non-ruptured hepatocellular carcinoma. The Medical journal of Australia. 2020;212(6):277-8.
8.    Garg M, Royce SG, Tikellis C, Shallue C, Batu D, Velkoska E, et al. Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target? Gut. 2020;69(5):841-51.
9.    French J, van der Mei I, Simpson S, Jr., Ng J, Angus P, Lubel J, et al. Increasing prevalence of primary biliary cholangitis in Victoria, Australia. Journal of gastroenterology and hepatology. 2020;35(4):673-9.
10.    Con D, Buckle A, Nicoll AJ, Lubel JS. Epidemiology and outcomes of marked elevations of alanine aminotransferase >1000 IU/L in an Australian cohort. JGH Open. 2020;4(2):106-12.
11.    Ji F, Yeo YH, Wei MT, Ogawa E, Enomoto M, Lee DH, et al. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. Journal of hepatology. 2019.
12.    Williams J, Lucarelli N, Nicoll A, Lubel J. Real-world Australian data reflect very high sustained virologic response at 12 weeks with direct acting antiviral therapy for hepatitis C and suggests highly achievable even in those without an end-of-treatment response. Internal medicine journal. 2019;49(5):666-9.
13.    Garg M, Royce SG, Tikellis C, Shallue C, Sluka P, Wardan H, et al. The intestinal vitamin D receptor in inflammatory bowel disease: inverse correlation with inflammation but no relationship with circulating vitamin D status. Therap Adv Gastroenterol. 2019;12:1756284818822566.
14.    Roberts SK, Gazzola A, Lubel J, Gow P, Bell S, Nicoll A, et al. Treatment choice for early-stage hepatocellular carcinoma in real-world practice: impact of treatment stage migration to transarterial chemoembolization and treatment response on survival. Scand J Gastroenterol. 2018:1-8.
15.    Hong TP, Gow PJ, Fink M, Dev A, Roberts SK, Nicoll A, et al. Surveillance improves survival of patients with hepatocellular carcinoma: a prospective population-based study. The Medical journal of Australia. 2018;209(8):348-54.
16.    Bloom S, Kemp W, Nicoll A, Roberts SK, Gow P, Dev A, et al. Liver stiffness measurement in the primary care setting detects high rates of advanced fibrosis and predicts liver-related events in hepatitis C. Journal of hepatology. 2018;69(3):575-83.
17.    Garg M, Rosella O, Rosella G, Wu YQ, Lubel JS, Gibson PR. Evaluation of a 12-week targeted vitamin D supplementation regimen in patients with active inflammatory bowel disease. Clinical Nutrition. 2018;37(4):1375-82.
18.    Lubel J, Strasser S, Stuart KA, Dore G, Thompson A, Pianko S, et al. Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir +/- ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study. Antivir Ther. 2017.
19.    Mgaieth S, Kemp W, Gow P, Fink M, Lubel J, Nicoll A, et al. Impact of viral hepatitis aetiology on survival outcomes in hepatocellular carcinoma: A large multicentre cohort study. J Viral Hepat. 2017.
20.    Lubel J, Chivers S, Taylor D, Capuano B. Testing of direct acting antiviral agents purchased overseas: a necessary precaution to protect patients? Internal medicine journal. 2016;46(9):1111-3.
21.    Hong TP, Gow P, Fink M, Dev A, Roberts S, Nicoll A, et al. Novel Population-Based Study Finding Higher Than Reported Hepatocellular Carcinoma Incidence Suggests an Updated Approach Is Needed. Hepatology. 2016;63(4):1205-12.
22.    Doyle A, Marsh P, Gill R, Rodov M, Mohsen W, Varma P, et al. Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study. Scand J Gastroenterol. 2016;51(8):979-85.
23.    Ding NS, Nguyen T, Iser DM, Hong T, Flanagan E, Wong A, et al. Liver stiffness plus platelet count can be used to exclude high-risk oesophageal varices. Liver Int. 2016;36(2):240-5.
24.    Asthana AK, Lubel JS, Kohn GP. Novel association of achalasia with hereditary sensory and motor neuropathy with sensorineural deafness. Diseases of the Esophagus. 2016;29(6):691-4.
25.    Vasudevan A, Spanger M, Lubel JS. Abdominal Pain Following Drug-eluting Bead Transarterial Chemoembolization. J Clin Exp Hepatol. 2015;5(1):93-4.
26.    Vasudevan A, Spanger M, Lubel JS. Abdominal pain following drug-eluting bead transarterial chemoembolisation. J Clin Exp Hepatol. 2015;5(1):105.
27.    Vasudevan A, Lubel JS. New-onset of celiac disease during interferon-based therapy for hepatitis C. Gastroenterology report. 2015;3(1):83-5.
28.    Philpott H, Lubel J, Nandurkar S. Letter: colestyramine for chronic unexplained diarrhoea - promising but much to learn? Alimentary pharmacology & therapeutics. 2015;42(3):388.
29.    Parthasarathy N, Hosking P, Lubel J. Obscure Upper Gastrointestinal Bleeding in the Presence of Jaundice and Abdominal Pain. Gastroenterology. 2015;149(4):874-5.
30.    Kemp W, Levy M, Weltman M, Lubel J, Ala. Australian Liver Association (ALA) expert consensus recommendations for the use of transient elastography in chronic viral hepatitis. Journal of gastroenterology and hepatology. 2015;30(3):453-62.
31.    Janko N, Nguyen TC, Lubel J. Looking beyond the scope: recurrent rectal bleeding in a young woman. Gut. 2015;64(7):1119-+.
32.    Garg M, Burrell LM, Velkoska E, Griggs K, Angus PW, Gibson PR, et al. Upregulation of circulating components of the alternative renin-angiotensin system in inflammatory bowel disease: A pilot study. Journal of the renin-angiotensin-aldosterone system : JRAAS. 2015;16(3):559-69.
33.    Doyle JS, Wilkinson AL, Chivers S, Iser DM, Thompson AJ, Bowden DS, et al. Natural history and response to treatment of hepatitis C genotype-1b infection from a health-care associated, single source outbreak. Journal of Viral Hepatitis. 2015;22:15-6.
34.    Roberts SK, Mitchell J, Leung R, Booth D, Bollipo S, Ostapowicz G, et al. Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies. Journal of gastroenterology and hepatology. 2014;29(1):179-84.
35.    Dwyer JP, Hosking P, Lubel J. Multiple Liver Lesions in a Patient With Positive Hepatitis C Serology and Elevated AFP: Is It HCC? Gastroenterology. 2014;147(3):E12-E3.
36.    Dang LJ, Lubel JS, Gunatheesan S, Hosking P, Su J. Drug-induced lupus and autoimmune hepatitis secondary to infliximab for psoriasis. Australasian Journal of Dermatology. 2014;55(1):75-9.
37.    Tang Y, Asthana A, Lubel J. Unusual cause of hiccup and abdominal pain after gastric variceal obliteration. Gastroenterology. 2013;144(2):e1-2.
38.    Nalankilli K, Lubel J. Elevated serum aminotransferases secondary to rippling muscle disease. Case reports in gastroenterology. 2013;7(2):234-9.
39.    Lim EJ, Spanger M, Lubel JS. Gallbladder perforation following transarterial chemoembolisation; a rare but serious complication. Frontline Gastroenterology. 2013;4(2):135-7.
40.    Garg M, Rosella O, Lubel JS, Gibson PR. Association of Circulating Vitamin D Concentrations with Intestinal but Not Systemic Inflammation in Inflammatory Bowel Disease. Inflammatory bowel diseases. 2013;19(12):2634-43.
41.    Ng A, Spanger M, Lubel JS. Hepatobiliary and Pancreatic: Emphysematous gastritis with hepatic portal venous gas. Journal of gastroenterology and hepatology. 2012;27(6):1130-.
42.    Lubel JS, Mahindra P. Spontaneous Submucosal Esophageal Hematoma: A Cause of Severe Thoracic Back Pain. Clin Gastroenterol Hepatol. 2012;10(4):A23-A.
43.    Lim EJ, Lubel JS. Hepatitis Without Hepatitis. Am J Gastroenterol. 2012;107(5):790-.
44.    Kazi S, Spanger M, Lubel J. Pulmonary embolism of cyanoacrylate glue following endoscopic Injection of gastric varices. Journal of gastroenterology and hepatology. 2012.
45.    Ward M, Rees C, Asthana AK, Lubel J. Colonic Perforation During Percutaneous Endoscopic Gastrostomy Tube Insertion With Subsequent Bumper Migration Into Colon. Clin Gastroenterol Hepatol. 2011;9(12):E128-E.
46.    Lubel JS, Herath CB, Tchongue J, Grace J, Jia ZY, Spencer K, et al. Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat. Clin Sci. 2009;117(11-12):375-86.
47.    Herath CB, Lubel JS, Jia ZY, Velkoska E, Casley D, Brown L, et al. Portal pressure responses and angiotensin peptide production in rat liver are determined by relative activity of ACE and ACE2. Am J Physiol-Gastroint Liver Physiol. 2009;297(1):G98-G106.
48.    Lubel JS, Herath CB, Velkoska E, Casley DJ, Burrell LM, Angus PW. Angiotensin converting enzyme 2 (ACE2) activity in fetal calf serum: implications for cell culture research. Cytotechnology. 2008;58(3):119-26.
49.    Lubel JS, Angus PW. Preventing hepatitis B virus reactivation following immunosuppressive therapy - Reply. Internal medicine journal. 2008;38(7):617-8.
50.    Lubel JS, Angus PW, Gow PJ. Accidental paracetamol poisoning. Med J Aust. 2007;186(7):371-2.
51.    Herath CB, Warner FJ, Lubel JS, Dean RG, Jia Z, Lew RA, et al. Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis. Journal of hepatology. 2007;47(3):387-95.
52.    Gow PJ, Warrilow S, Lontos S, Lubel J, Wongseelashote S, MacQuillan GC, et al. Time to review the selection criteria for transplantation in paracetamol-induced fulminant hepatic failure? Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2007;13(12):1762-3.
53.    Lubel JS, Burrel LM, Levidiotis V. An unexpected cause of macroscopic haematuria. Med J Aust. 2005;183(6):321-3.
54.    Lubel J, Wiley M. Gastrointestinal: Foreign bodies and diverticulitis. Journal of gastroenterology and hepatology. 2005;20(4):649-.
55.    Hokama A, Okamoto T, Nakama M, Miyagi S, Kishimoto K, Tomiyama R, et al. Gastrointestinal: Aortoduodenal fistulae. Journal of gastroenterology and hepatology. 2005;20(6):951-.
 
Reviews (56-75)


56.    Doyle J, Raggatt M, Slavin M, McLachlan SA, Strasser SI, Sasadeusz JJ, et al. Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement. The Medical journal of Australia. 2019;210(10):462-8.
57.    Lewis D, Bloom S, Nicoll A, Kemp W, Lubel J. How to Treat LIver Cirrhosis. Australian Doctor. 2018.
58.    Thompson AJ. Australian recommendations for the management of hepatitis C virus infection: a consensus statement. The Medical journal of Australia. 2016;204(7):268-72.
59.    Richmond JA, Sheppard-Law S, Mason S, Warner SL. The Australasian Hepatology Association consensus guidelines for the provision of adherence support to patients with hepatitis C on direct acting antivirals. Patient Prefer Adherence. 2016;10:2479-89.
60.    Philpott H, Nandurkar S, Lubel J, Gibson PR. Food, fibre, bile acids and the pelvic floor: An integrated low risk low cost approach to managing irritable bowel syndrome. World J Gastroentero. 2015;21(40):11379-86.
61.    Bloom S, Kemp W, Lubel J. Portal hypertension: pathophysiology, diagnosis and management. Internal medicine journal. 2015;45(1):16-26.
62.    Philpott HL, Nandurkar S, Lubel J, Gibson PR. Drug-induced gastrointestinal disorders. Postgraduate Medical Journal. 2014;90(1065):411-9.
63.    Philpott HL, Nandurkar S, Lubel J, Gibson PR. Republished: Drug-induced gastrointestinal disorders. Postgraduate Medical Journal. 2014;90(1065):411-9.
64.    Philpott HL, Nandurkar S, Lubel J, Gibson PR. Drug-induced gastrointestinal disorders. Frontline Gastroenterology. 2014;5(1):49-57.
65.    Croagh CMN, Lubel JS. Natural history of chronic hepatitis B: Phases in a complex relationship. World J Gastroentero. 2014;20(30):10395-404.
66.    Asthana A, Lubel JS. Reactivation of latent viruses after treatment with biological therapies. Virus Adaptation and Treatment. 2014;2014(6):1-10.
67.    Philpott H, Nandurkar S, Lubel J, Gibson PR. Alternative investigations for irritable bowel syndrome. Journal of gastroenterology and hepatology. 2013;28(1):73-7.
68.    Croagh CM, Lubel J. Advances in the management of hepatitis C. Internal medicine journal. 2013;43(12):1265-71.
69.    Garg M, Lubel JS, Sparrow MP, Holt SG, Gibson PR. Review article: vitamin D and inflammatory bowel disease - established concepts and future directions. Alimentary pharmacology & therapeutics. 2012;36(4):324-44.
70.    Garg M, Angus PW, Burrell LM, Herath C, Gibson PR, Lubel JS. Review article: the pathophysiological roles of the renin-angiotensin system in the gastrointestinal tract. Alimentary pharmacology & therapeutics. 2012;35(4):414-28.
71.    Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: Diagnosis and management. Journal of gastroenterology and hepatology. 2010;25(5):864-71.
72.    Lubel JS, Herath CB, Burrell LM, Angus PW. Liver disease and the renin-angiotensin system: Recent discoveries and clinical implications. Journal of gastroenterology and hepatology. 2008;23(9):1327-38.
73.    Warner FJ, Lubel JS, McCaughan GW, Angus PW. Liver fibrosis: a balance of ACEs? Clin Sci. 2007;113(3-4):109-18.
74.    Lubel JS, Testro AG, Angus PW. Hepatitis B virus reactivation following immunosuppressive therapy: Guidelines for prevention and management. Internal medicine journal. 2007;37(10):705-12.
75.    Lubel JS, Angus PW. Modern management of portal hypertension. Internal medicine journal. 2005;35(1):45-9.

 

 
Books and book chapters


76.    Lubel JSW, F. J.; Angus, P. W. The Role of the Renin-Angiotensin System in Hepatic Fibrosis. Frontiers in Research of the Renin-Angiotensin System on Human Disease. 2008:113-34.

 
Keynote addresses


77.    Lubel J, editor How to deal with patients with active hepatitis B and C. European Society of Medical Oncology; 2012 Sep; Vienna, Austria.
78.    Lubel J, editor Hepatitis B reactivation following chemotherapy. ESMO Asia Pacific meeting 2015; Singapore.
79.    Lubel J, editor Australian Real World Experience in People with Advanced Liver Disease. 23rd National Symposium on hepatitis B and C; 2016.

 
Conference presentations and posters 


80.    Lewis D, Bloom S, Nicoll A, Kemp W, Roberts S, Gow P, et al. Community Approach Targeting Cirrhosis and Hepatocellular Carcinoma (CATCH) study: Hepatitis B virus infection, screening patterns for hepatocellular carcinoma between general practitioners and non-GP specialists. Journal of gastroenterology and hepatology. 2019;34:65-.
81.    Lewis D, Bloom S, Kemp W, Nicoll A, Roberts S, Gow P, et al. Community Approach Targeting Cirrhosis and Hepatocellular Carcinoma (CATCH) study: Medium-term results. Journal of gastroenterology and hepatology. 2019;34:65-6.
82.    Le S, Ratnam D, Van Leest R, Kemp W, Roberts S, Nicoll A, et al. Real-world efficacy of long-term entecavir and tenofovir in patients with chronic hepatitis B. Journal of gastroenterology and hepatology. 2019;34:95-.
83.    Ji F, Wei MT, Yeo YH, Wei B, Ogawa E, Lee DH, et al. Sustained virologic response (SVR) to direct-acting antiviral (DAA) therapy in patients with chronic hepatitis C virus (HCV) infection and hepatocellular carcinoma (HCC): a systematic review and meta-analysis.  EASL; Paris, France2018.
84.    Hansa F, Nicoll A, Le S, Knowles S, Lubel J, Halliday J, et al. Improving assessment of hepatic encephalopathy in outpatient
clinics.  EASL; Paris, France2018.
85.    Worland T, Trinh A, Hosking P, Lubel J, Nicoll A. Severe liver steatosis from L-asparaginase: Case report and a single-center series. Journal of gastroenterology and hepatology. 2017;32:113-.
86.    Williams J, Lucarelli N, Pham D, Douglas L, Chivers S, Day C, et al. Real-world Australian data replicate very high sustained virological response at 12 weeks (SVR12) results reported in clinical trials and suggest SVR12 is highly achievable even in those without an end-of-treatment response. Journal of gastroenterology and hepatology. 2017;32:84-.
87.    Smith R, Lubel J, Nicoll AJ. Primary biliary cholangitis in Asian Australians: Is it different? Journal of gastroenterology and hepatology. 2017;32:107-8.
88.    Pham D, Yeoh SW, Lubel J, Nicoll AJ. A new predictor of outcome for cirrhotic patients in the intensive care unit (pre-acute deterioration Child-Turcotte-Pugh score): The CHIP study. Journal of gastroenterology and hepatology. 2017;32:104-.
89.    Lucarelli N, Buckle A, Lewis D, Chivers S, Day C, Parsons N, et al. Defining a new phase in hepatitis B: The role of viral load in immune escape. Journal of gastroenterology and hepatology. 2017;32:73-4.
90.    Lubel JS, Pianko S, Thompson A, Strasser S, Dore G, Stuart K, et al. Very high real-world efficacy of ritonavir boosted paritaprevir with ombitasvir and dasabuvir plus /- ribavirin in hepatitis C genotype 1 in patients with advanced fibrosis -Final results of the REV1TAL study. Journal of hepatology. 2017;66(1):S521-S.
91.    Hong TP, Gow P, Fink M, Dev A, Roberts S, Nicoll A, et al. Direct costs analysis of hepatocellular carcinoma treatment using a population-based Melbourne clinical cohort. Journal of gastroenterology and hepatology. 2017;32:96-.
92.    Con D, Buckle A, Nicoll A, Lubel J. Severe liver injury in a large tertiary center cohort: Establishing etiology, outcomes, and prognostic factors. Journal of gastroenterology and hepatology. 2017;32:91-.
93.    Clayton-Chubb DI, Buckle A, Ho M, Ting CCY, Chin SJH, Lucarelli N, et al. Applying the REACH-B model to an Australian chronic hepatitis B cohort underestimates the incidence of hepatocellular carcinoma. Journal of gastroenterology and hepatology. 2017;32:68-.
94.    Clayton-Chubb D, Buckle A, Ho M, Chia G, Beaumont-Kelly HT, Lucarelli N, et al. Demographics and screening costs for hepatocellular carcinoma in an Australian chronic hepatitis B cohort. Journal of gastroenterology and hepatology. 2017;32:90-1.
95.    Bloom S, Lubel J, Nicoll A, Gow P, Dev A, Roberts S, et al. Comparison of direct-acting antiviral therapy for hepatitis C between specialist centers and primary care: Efficacy and adherence to response assessment. Journal of gastroenterology and hepatology. 2017;32:65-6.
96.    Bloom S, Kemp W, Dev A, Gow P, Nicoll A, Roberts S, et al. Community Approach Targeting Cirrhosis and Hepatocellular carcinoma (CATCH): community prevalence of advanced fibrosis in viral hepatitis. Journal of hepatology. 2017;66(1):S673-S.
97.    Yeoh SW, Parthasarathy N, Vasudevan A, Patrick D, Lubel J, Nicoll A. Adding Alpha-Fetoprotein to Ultrasound in Hepatocellular Carcinoma Screening Leads to High Rates of Over-Investigation With Few Additional Diagnoses. Gastroenterology. 2016;150(4):S1126-S.
98.    Tan N, Bloom S, Roberts S, Lubel J, Kemp W. Using age cohorts identifies chronic viral hepatitis patients most at risk of liver fibrosis. Journal of gastroenterology and hepatology. 2016;31:117-8.
99.    Tan J, Lewis D, Bloom S, Nicoll A, Lubel J. Oesophageal food bolus obstruction; medical and endoscopic management outcomes. Journal of gastroenterology and hepatology. 2016;31:48-.
100.    Lubel J, Mitchell J, Pianko S, Thompson AJ, Iser DM, Gazzola A, et al. Excellent SVR12 rates with Viekira Pak in a real-world cohort of HCV Genotype 1 patients predominantly with cirrhosis - the Australian REV1TAL Study. Hepatology. 2016;64:483A-4A.
101.    Lubel J, Mitchell J, Pianko S, Thompson AJ, Iser DM, Gazzola A, et al. Frequency and severity of biochemical abnormalities with paritaprevir/ritonavir/ombitasvir +/- ribavirin in a real-world cohort of HCV Genotype 1 patients - predictors and clinical significance. Hepatology. 2016;64:442A-A.
102.    Lubel J, Mitchell J, Pianko S, Thompson A, Iser D, Gazzola A, et al., editors. Excellent SVR12 rates with Viekira Pak in a real-world cohort of HCV Genotype 1 patients predominantly with cirrhosis - the Australian REV1TAL Study. New Zealand Gastroenterology Annual Scientific meeting; 2016; Hamilton, New Zealand.
103.    Lubel J, Mitchell J, Pianko S, Thompson A, Iser D, Gazzola A, et al. Frequency and severity of hyperbilirubinaemia with Viekira Pak in a real-world cohort of HCV genotype 1 patients - Predictors and clinical significance. Journal of gastroenterology and hepatology. 2016;31:78-9.
104.    Lubel J, Mitchell J, Pianko S, Thompson A, Iser D, Gazzola A, et al. Excellent SVR12 rates with Viekira Pak in a real-world cohort of HCV genotype 1 patients predominantly with cirrhosis - the Australian REV1TAL study. Journal of gastroenterology and hepatology. 2016;31:77-8.
105.    Lewis D, Lee SY, Dwivedi S, Janko N, Trezise K, Nicoll A, et al. Natural history of immune-escape hepatitis B infection without flare: long term follow up. Journal of gastroenterology and hepatology. 2016;31:76-.
106.    Gazzola A, Lubel J, Gow P, Bell S, Nicoll A, Dev A, et al. Outcome of treatment in BCLC-0/A HCC patients in real world practice: impact of treatment response and treatment stage migration in overall survival (OS). Hepatology. 2016;64:677A-8A.
107.    Garg M, Royce SG, Tikellis C, Batu D, Shallue C, Sluka P, et al. Key alternative RAS components are reduced in inflamed colon in IBD: potential therapeutic targets. Journal of gastroenterology and hepatology. 2016;31:124-.
108.    Bloom SD, Lubel J, Dev A, Gow P, Nicoll A, Roberts SK, et al. Community Approach Targeting Cirrhosis and Hepatocellular Carcinoma (CATCH) - Community Cirrhosis Prevalence in Viral Hepatitis. Hepatology. 2016;64:863A-4A.
109.    Bloom SD, Lewis D, Smith C, Kemp WW, Lubel J. 4AGP-A novel algorithm using indirect biomarkers out-performs established scores for detecting patients with elevated liver stiffness. Hepatology. 2016;64:94A-A.
110.    Bloom S, Lubel J, Dev A, Gow P, Nicoll A, Roberts S, et al. Hepatocellular carcinoma surveillance in primary care. Journal of gastroenterology and hepatology. 2016;31:93-.
111.    Bloom S, Lubel J, Dev A, Gow P, Nicoll A, Roberts S, et al. Are indirect biomarkers enough for community treatment? Journal of gastroenterology and hepatology. 2016;31:91-2.
112.    Bloom S, Kemp W, Dev A, Gow P, Nicoll A, Roberts S, et al. Community approach targeting cirrhosis and hepatocellular carcinoma (CATCH) - community cirrhosis prevalence in viral hepatitis. Journal of gastroenterology and hepatology. 2016;31:92-.
113.    Yeoh S, Parthasarathy N, Vasudevan A, Patrick D, Lubel J, Nicoll A. Adding alpha-fetoprotein to ultrasound in hepatocellular carcinoma screening leads to high rates of over-investigation with few additional diagnoses. Journal of gastroenterology and hepatology. 2015;30:116-.
114.    Vasudevan A, Lubel J, Denyar N, Nalankilli K, Jackson A, Greenhalgh J, et al. The pattern of alpha-fetoprotein level has greater diagnostic value compared to isolated values in predicting the presence of hepatocellular carcinoma. Journal of hepatology. 2015;62:S438-S9.
115.    Vasudevan A, Lewis D, Bohra A, Nicoll A, Lubel J. Angiographic embolisation for non-variceal upper gastrointestinal bleeding in high risk patients who fail endoscopic therapy: outcomes from a single centre. Journal of gastroenterology and hepatology. 2015;30:65-.
116.    Vasudevan A, Jackson A, Lewis D, Chong J, Raghunath A, Love J, et al. The use of liver biochemistry to determine hepatocellular and cholestatic causes of jaundice. Journal of gastroenterology and hepatology. 2015;30:113-4.
117.    Mohammed A, Patlolla JMR, Zhang YT, Biddick L, Madka V, Li Q, et al. Omeprazole alone, or in combination with Aspirin inhibits azoxymethane-induced colon adenoma progression to adenocarcinoma and carcinoma invasion in F344 rat model. Cancer Research. 2015;75.
118.    Mgaieth S, Kemp WW, Gow P, Fink MA, Knight VH, Dev AT, et al. Impact of Viral Hepatitis Etiology on Survival Outcomes in Patients with Hepatocellular Carcinoma: A Large Multicentre Study. Hepatology. 2015;62:452A-3A.
119.    Lewis D, Yeoh S, Ye B, Bloom S, Nicoll A, Lubel J. Treatment delay: the effect of uncertainty with the anticipated arrival of direct acting antivirals for hepatitis C. Journal of gastroenterology and hepatology. 2015;30:87-.
120.    Lewis D, Vasudevan A, Jackson A, Chong J, Raghunath A, Love J, et al. Hyperbilirubinaemia: causes and predictors of mortality. Journal of gastroenterology and hepatology. 2015;30:107-.
121.    Lewis D, Janko N, Trezise K, Nicoll A, Lubel J. The natural history of immune escape hepatitis B infection without biochemical flare: treat now or wait. Journal of gastroenterology and hepatology. 2015;30:88-9.
122.    Janko N, Teo M, Bloom S, Shallue C, Nicoll A, Lubel J. Hepatocellular carcinoma surveillance in chronic hepatitis B patients at a Victorian hospital. Journal of gastroenterology and hepatology. 2015;30:88-.
123.    Janko N, Bohra A, Nicoll A, Lubel J. Presentation and management of acute symptomatic hepatitis B infection at an Australian hospital. Journal of gastroenterology and hepatology. 2015;30:87-8.
124.    Hong T, Gow P, Fink MA, Dev AT, Roberts SK, Nicoll AJ, et al. Hepatocellular Carcinoma Surveillance Is Associated With Improved Survival And Can Be Targeted To High Risk Populations. Hepatology. 2015;62:432A-A.
125.    Hong T, Gow P, Fink M, Dev A, Roberts S, Nicoll A, et al. Surveillance is associated with improved survival in patients with hepatocellular carcinoma and can be targeted to high risk populations. Journal of gastroenterology and hepatology. 2015;30:183-.
126.    Garg M, Shallue C, Royce SG, Tikellis C, Sluka P, Wardan H, et al. Alteration of the renin-angiotensin system in the circulation, terminal ileum and colon in patients with inflammatory bowel disease: a potential novel therapeutic target. Journal of gastroenterology and hepatology. 2015;30:128-.
127.    Garg M, Shallue C, Royce SG, Sluka P, Wardan H, McFarlane A, et al. Comprehensive characterisation of the vitamin d receptor in the terminal ileum and colon in patients with and without inflammatory bowel disease. Journal of gastroenterology and hepatology. 2015;30:127-.
128.    Garg M, Jackson A, Britto K, Beswick L, Lukies M, Gibson PR, et al. Medications blocking the renin-angiotensin system may influence disease outcomes in patients with inflammatory bowel disease. Journal of gastroenterology and hepatology. 2015;30:127-8.
129.    Garg M, Barr A, Rosella O, Rosella G, Gibson PR, Lubel JJ. A specified oral vitamin d supplementation regimen is effective for increasing serum 25(oh) vitamin d and is associated with a reduction in disease activity scores. Journal of gastroenterology and hepatology. 2015;30:126-7.
130.    Chand SK, Lewis D, Chomlak D, Bloom S, Lubel J. Bowel wall thickening on computerised tomography- clinical and endoscopic significance. Journal of gastroenterology and hepatology. 2015;30:122-.
131.    Bloom S, Kemp W, Dev A, Gow P, Nicoll A, Roberts S, et al. Community screening for cirrhosis using liver stiffness measurement - a pilot study. Journal of gastroenterology and hepatology. 2015;30:98-.
132.    Bloom S, Kemp W, Dev A, Gow P, Nicoll A, Roberts S, et al. Correlation of clinical stigmata to the severity of chronic liver disease. Journal of gastroenterology and hepatology. 2015;30:96-7.
133.    Vasudevan A, Denyar N, Nalankilli K, Jackson A, Scanlon CP, Greenhalgh JP, et al. The pattern of alpha-fetoprotein level has greater diagnostic value compared to isolated values in predicting the presence of hepatocellular carcinoma. Journal of gastroenterology and hepatology. 2014;29:68-.
134.    Van Leest RL, Ratnam DT, Kronborg I, Lubel J, Roberts S, Nicholl A, et al. An entecavir (ETV) and tenofovir (TDF) real world study - A retrospective review of long term entecavir and tenofovir therapy in chronic hepatitis B in Australia. Journal of gastroenterology and hepatology. 2014;29:163-4.
135.    Patrick D, Bloom S, Spanger M, Ramachandran V, Lubel J. CT hepatic angiography versus biopsy in the diagnosis of radiologic atypical hepatocellular carcinoma - an evaluation of real life practice. Journal of gastroenterology and hepatology. 2014;29:74-.
136.    Janko N, Shallue C, Croagh C, Lubel J. Identifying chronic hepatitis B patients who may be suitable for monitoring in the community: predictors of stability in immune-control phase. Journal of gastroenterology and hepatology. 2014;29:157-.
137.    Janko N, Shallue C, Croagh C, Lubel J. Deficiencies in the current classification of chronic hepatitis B phases: experiences from real-world practice. Journal of gastroenterology and hepatology. 2014;29:157-8.
138.    Janko N, Shallue C, Croagh C, Lubel J. Real-world experience of tenofovir and entecavir for the treatment of chronic hepatitis B in a large metropolitan health service in Victoria. Journal of gastroenterology and hepatology. 2014;29:156-7.
139.    Hong T, Thompson AJ, Gow P, Fink MA, Dev AT, Knight VH, et al. Cancer Registries Underestimate Hepatocellular Carcinoma Incidence: An Independent Population-Based Epidemiological Study. Hepatology. 2014;60:876A-7A.
140.    Hong T, Thompson A, Gow P, Fink M, Dev A, Knight V, et al. Cancer registries underestimate hepatocellular carcinoma incidence: an independent population-based epidemiological study. Journal of gastroenterology and hepatology. 2014;29:96-.
141.    Fulforth JM, Newnham ED, Lubel J. Uniformity of practice in the absence of an evidence base: overuse of PPI infusions in a tertiary referral centre. Journal of gastroenterology and hepatology. 2014;29:51-.
142.    Ding NS, Kemp W, Nguyen T, Iser DM, Hong T, Flanagan E, et al. Elastography Plus Platelet Count Rather Than Endoscopy to Screen for Clinically Significant Esophageal Varices. Gastroenterology. 2014;146(5):S984-S5.
143.    Dev AT, Mitchell J, Polkinghorne K, Skoien R, Stuart K, Cheng W, et al. Treatment safety and efficacy of Boceprevir-based triple therapy in genotype 1 hepatitis C: the Australian multi-centre Boceprevir real world experience (SABRE-C). Hepatology. 2014;60:674A-A.
144.    Dev A, Mitchell J, Polkinghorne K, Skoien R, Stuart K, Cheng W, et al. Treatment safety and efficacy of boceprevir-based triple therapy in genotype 1 hepatitis C: the Australian multicenter boceprevir real world experience (SABRE-C). Journal of gastroenterology and hepatology. 2014;29:70-.
145.    Stanton D, Lewis DJ, Croagh C, Lubel JS. Treatment outcomes of patients with gastric varices with high risk stigmata or active bleeding - lessons learned from a case series. Journal of gastroenterology and hepatology. 2013;28:58-.
146.    Lubel JS, Smith JD. Bony metastases from hepatocellular carcinoma occurs commonly and impacts on management - if you don't look you don't find! Journal of gastroenterology and hepatology. 2013;28:62-.
147.    Lim EJ, Lubel JS. Liver stiffness measurement differs according to the phase of chronic hepatitis B. Journal of gastroenterology and hepatology. 2013;28:59-60.
148.    Lewis DJ, Kalra B, Chiu WL, Sajeev J, Dickins M, Lubel J. Thyroid dysfunction in patients treated with interferon & ribavirin for hepatitis C virus infection. Journal of gastroenterology and hepatology. 2013;28:58-9.
149.    Hong T, Thompson A, Gow P, Fink M, Ryan M, Dev A, et al. High incidence of hepatocellular carcinoma in melbourne: Results from a population-based epidemiological study. Journal of gastroenterology and hepatology. 2013;28:76-.
150.    Garg M, Rosella O, Lubel JS, Gibson PR. Circulating levels of total, free and bioavailable 25(OH) vitamin d inversely correlate with intestinal but not systemic inflammation in patients with inflammatory bowel disease. Journal of gastroenterology and hepatology. 2013;28:102-.
151.    Garg M, Rosella O, Lubel J, Gibson PR. Total, Free and Bioavailable 25(OH) Vitamin D Inversely Correlate With Faecal Calprotectin in Patients With Inflammatory Bowel Disease. Gastroenterology. 2013;144(5):S821-S2.
152.    Garg M, Jackson A, Lukies M, Gibson PR, Lubel JS. Medications blocking the renin-angiotensin system may influence disease activity in patients with inflammatory bowel disease. Journal of gastroenterology and hepatology. 2013;28:101-2.
153.    Dwyer JP, Croagh C, Mascaro J, Lubel J. Relationship between 6-MMP and 6-TGN levels and hepatotoxicity in allopurinol-thiopurine cotherapy. Journal of gastroenterology and hepatology. 2013;28:63-.
154.    Chong JA, Lewis DJ, Lubel JS. Spontaneous rupture of hepatocellular carcinoma: A case series. Journal of gastroenterology and hepatology. 2013;28:58-.
155.    Tang Y, Lau WH, Chung AR, Lubel JS. Ultrasonography evaluation of the fibrosis stage in chronic liver disease - correlation with liver stiffness measurement from fibroscan. Journal of gastroenterology and hepatology. 2012;27:91-.
156.    Qian SY, Leong CH, Clements AE, Lubel JS. Entering the new era of direct acting antivirals for chronic hepatitis C - where have we come from? Current all-genotype results of the Eastern Health Hepatology Unit. Journal of gastroenterology and hepatology. 2012;27:175-6.
157.    Lubel JS, Goodwin MD, Spanger M, Arachchi NJ, Bell S, Dev A, et al. Considerable variation in approach to chemoembolisation by interventional radiologists treating hepatocellular carcinoma - is standardised treatment feasible? Journal of gastroenterology and hepatology. 2012;27:87-.
158.    Lim EJ, Clements AE, Lubel JS. ASMA predicts for pre-treatment liver biopsy and delays normalisation of ALT during the first 12 weeks of therapy with pegylated interferon and ribavirin but has no impact on SVR. Journal of gastroenterology and hepatology. 2012;27:85-.
159.    Garg M, Rosella O, Rose R, Lubel JS, Gibson P. Total, free and bioavailable vitamin D inversely correlate with faecal calprotectin in patients with inflammatory bowel disease (IBD). Journal of gastroenterology and hepatology. 2012;27:103-.
160.    Garg M, Griggs K, Velkoska E, Rosella O, Angus P, Burrell L, et al. Circulating components of the alternative renin-angiotensin system are upregulated in patients with inflammatory bowel disease. Journal of gastroenterology and hepatology. 2012;27:103-4.
161.    Bloom S, Cheng RKY, Lim L, Gow P, Lubel JS. Conventional transarterial chemoembolization versus doxorubicin bead transarterial chemoembolization for the treatment of hepatocellular carcinoma, a retrospective cohort study. Journal of gastroenterology and hepatology. 2012;27:70-1.
162.    Asthana AK, Choong J, Lubel JS. Education does not improve hepatitis B screening uptake in those receiving cytotoxic chemotherapy - time for alternative strategies. Journal of gastroenterology and hepatology. 2012;27:162-.
163.    Pham J, Vasudevan A, Herath D, Ong MD, Lubel JS. Response to pharmacological treatment of chronic hepatitis B: the Eastern Health experience. Journal of gastroenterology and hepatology. 2011;26:108-.
164.    Ong MD, Herath D, Pham J, Vasudevan AA, Lubel JS. Community referral patterns of chronic hepatitis B provide potential strategies to target low referral general practitioners. Journal of gastroenterology and hepatology. 2011;26:107-8.
165.    Mahindra P, Lewis DJ, Lubel JS. Markedly elevated serum transaminases in the hospital setting: pancreatobiliary and ischaemic causes are the most common. Journal of gastroenterology and hepatology. 2011;26:53-.
166.    Lewis DJ, Clements A, Mahindra P, Dickins ML, Day C, Chivers S, et al. Treatment of genotype 1 hepatitis C in a non-trial setting: surprisingly high sustained viral response. Journal of gastroenterology and hepatology. 2011;26:106-.
167.    Butt JE, Chong JA, Philpott HL, Spanger M, Lubel JS. Doxorubicin-eluting-bead chemoembolisation for hepatocellular carcinoma; a retrospective, single-centre analysis. Journal of gastroenterology and hepatology. 2011;26:54-.
168.    Ward MG, Asthana AK, Lubel JS. Hepatitis B screening uptake prior to cytotoxic chemotherapy for lymphoma-room for improvement? Journal of gastroenterology and hepatology. 2010;25:A135-A.
169.    Lubel JS, Herath CB, Jia Z, Tchongue J, Sievert W, Burrell LM, et al. New insights into the angiotensin 1-7/MAS receptor interaction from a murine model of hepatic fibrosis and hepatic stellate cell culture. Journal of hepatology. 2008;48:S182-S.
170.    Lubel JS, Herath C, Jia Z, Burrell LM, Angus P. Ang 1-7 fails to potentiate acetylcholine vasodilatation in the preconstricted in situ perfused cirrhotic rat liver. Gut. 2008;57:A82-A.
171.    Lubel JS, Herath CB, Jia ZY, Burrell LM, Angus PW. Angiotensin 1-7 reduces bile duct proliferation and hepatic fibrosis in the bile duct ligated rat. Hepatology. 2007;46(4):706A-7A.
172.    Herath CB, Lubel JS, Warner FJ, Jia Z, Dean RG, Lew RA, et al. Chronic liver injury is associated with the upregulation of the ACE2-angiotensin-(1-7)-Mas axis in the rat. Journal of hepatology. 2007;46:S128-S.
173.    Testro AG, Clonan MA, Patterson SJ, Lubel JS, Angus PW, Gow PJ. Outcome following acute upper gastrointestinal haemorrhage in a Melbourne teaching hospital 2005. Journal of gastroenterology and hepatology. 2006;21:A255-A.
174.    Lubel JS, Herath CB, Warner FJ, Jia ZY, Burrell LM, Angus PW. Upregulation of the ACE2/ANG1-7/MAS receptor axis in the bile duct ligation (BDL) model of hepatic fibrosis does not affect hepatic sinusoidal resistance. Journal of gastroenterology and hepatology. 2006;21:A332-A.
175.    Herath CB, Warner FW, Lubel J, Dean R, Lew R, Smith I, et al. The balance between hepatic ACE2 & ACE determines plasma levels of vasodilator peptide angiotensin-(1-7) in experimental biliary fibrosis. Journal of gastroenterology and hepatology. 2006;21:A325-A